S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Critical asset just had biggest fall on record (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

YS Biopharma (YS) Earnings Date, Estimates & Call Transcripts

$0.40
+0.01 (+2.56%)
(As of 02/27/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Apr. 22Estimated
Actual EPS
(Jan. 22)
-$0.16 Missed By -$0.16
Skip Charts & View Estimated and Actual Earnings Data

YS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

YS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

YS Biopharma Analyst EPS Estimates

Current Year EPS Consensus Estimate:($0.49) EPS
Next Year EPS Consensus Estimate: ($0.30) EPS

YS Earnings Date and Information

YS Biopharma last issued its quarterly earnings results on January 22nd, 2024. The reported ($0.16) EPS for the quarter. The company had revenue of $13.64 million for the quarter. YS Biopharma has generated $0.00 earnings per share over the last year. Earnings for YS Biopharma are expected to grow in the coming year, from ($0.49) to ($0.30) per share. YS Biopharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 22nd, 2024 based off prior year's report dates.

YS Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/22/2024
Estimated)
------- 
1/22/2024Q2 2024-($0.16)($0.16)($0.16)-$13.64 million
8/15/2023Q1 2024-($0.10)($0.10)($0.10)-$24.40 million
11/14/2022Q3 2022-$0.22+$0.22$0.22--
8/12/2022Q2 2022-$0.07+$0.07$0.07--
5/13/2022Q1 2022-$0.28+$0.28$0.28--
3/31/2022Q4 2021-$0.23+$0.23$0.23--












YS Biopharma Earnings - Frequently Asked Questions

When is YS Biopharma's earnings date?

YS Biopharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 22nd, 2024 based off last year's report dates. Learn more on YS's earnings history.

How much revenue does YS Biopharma generate each year?

YS Biopharma (NASDAQ:YS) has a recorded annual revenue of $100 million.

How much profit does YS Biopharma generate each year?

YS Biopharma (NASDAQ:YS) has a recorded net income of -$21.17 million. YS has generated $0.00 earnings per share over the last four quarters.

What is YS Biopharma's EPS forecast for next year?

YS Biopharma's earnings are expected to grow from ($0.49) per share to ($0.30) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:YS) was last updated on 2/28/2024 by MarketBeat.com Staff